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Abstract
In humans, a copy of the DUX4 retrogene is located in each unit of the D4Z4 macrosatellite repeat that normally comprises
8–100 units. The D4Z4 repeat has heterochromatic features and does not express DUX4 in somatic cells. Individuals with
facioscapulohumeral muscular dystrophy (FSHD) have a partial failure of somatic DUX4 repression resulting in the presence
of DUX4 protein in sporadic muscle nuclei. Somatic DUX4 derepression is caused by contraction of the D4Z4 repeat to 1–10
units (FSHD1) or by heterozygous mutations in genes responsible for maintaining the D4Z4 chromatin structure in a repres-
sive state (FSHD2). One of the FSHD2 genes is the structural maintenance of chromosomes hinge domain 1 (SMCHD1) gene.
SMCHD1 mutations have also been identified in FSHD1; patients carrying a contracted D4Z4 repeat and a SMCHD1 mutation
are more severely affected than relatives with only a contracted repeat or a SMCHD1 mutation. To evaluate the modifier role
of SMCHD1, we crossbred mice carrying a contracted D4Z4 repeat (D4Z4–2.5 mice) with mice that are haploinsufficient for
Smchd1 (Smchd1MommeD1 mice). D4Z4–2.5/Smchd1MommeD1 mice presented with a significantly reduced body weight and
developed skin lesions. The same skin lesions, albeit in a milder form, were also observed in D4Z4–2.5 mice, suggesting that
reduced Smchd1 levels aggravate disease in the D4Z4–2.5 mouse model. Our study emphasizes the evolutionary conservation
of the SMCHD1-dependent epigenetic regulation of the D4Z4 repeat array and further suggests that the D4Z4–2.5/
Smchd1MommeD1 mouse model may be used to unravel the function of DUX4 in non-muscle tissues like the skin.
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Introduction
DUX4 is a double homeobox transcription factor expressed in
the luminal cells of the testis (1) and in cleavage stage embryos
(2–4). A copy of the DUX4 retrogene is located in each unit of the
D4Z4 macrosatellite repeat at the subtelomere of chromosome
4q. This D4Z4 repeat is polymorphic in size and typically con-
sists of 8–100 D4Z4 repeat units (5–7). In most somatic cells, the
D4Z4 repeat has heterochromatic features and, likely due to
repeat-mediated epigenetic repression, does not express or
rarely expresses DUX4 (1,8–10). Individuals with FSHD, a com-
mon inherited myopathy that initially affects muscles of the
face, shoulder girdle, and upper arms, have a partial failure of
the epigenetic repression of the D4Z4 repeat, resulting in the
presence of DUX4 protein in a limited number of muscle
nuclei (1). This failure in epigenetic repression can be caused by
contraction of the D4Z4 repeat to 1–10 units (FSHD1) (5,6), by
heterozygous mutations in the SMCHD1 gene (FSHD2) (11), or in
rare cases by heterozygous mutations in the DNA methyltrans-
ferase 3B (DNMT3B) gene (FSHD2) (12). SMCHD1 and DNMT3B
both encode chromatin modifiers that seem to be necessary to
establish and/or maintain a repressive chromatin structure of
the D4Z4 repeat in somatic cells. SMCHD1 and DNMT3B muta-
tions have also been identified in FSHD1 families; patients that
carry both a contracted D4Z4 repeat and a FSHD2 mutation pre-
sent with a more severe clinical phenotype than relatives carry-
ing only the D4Z4 repeat contraction or the SMCHD1/DNMT3B
mutation (12–14). In agreement, enhanced DUX4 transcript lev-
els were measured in myotube cultures from FSHD1 patients
upon SMCHD1 knockdown (13).
To study the in vivo epigenetic regulation of the D4Z4 repeat
locus, we previously generated hemizygous transgenic mice
carrying either a control-sized D4Z4 repeat (D4Z4–12.5 mice) or
a FSHD-sized D4Z4 repeat (D4Z4–2.5 mice) (15). In these mice,
we demonstrated that the mechanism of epigenetic repression
of DUX4 in somatic cells seems to be conserved between mice
and man. Control D4Z4–12.5 mice present with DUX4 expres-
sion in the germline, but DUX4 is epigenetically repressed in so-
matic cells. In contrast, D4Z4–2.5 mice fail to efficiently repress
DUX4 in somatic cells. As a consequence, sporadic muscle nu-
clei express relatively abundant amounts of DUX4 protein (15).
Though the FSHD molecular hallmarks are conserved in D4Z4–
2.5 mice, we questioned whether modelling FSHD in rodents
will elicit the same pathological consequences as in human.
This is supported by the notion that, apart from an uncharacter-
ized eye phenotype, D4Z4–2.5 mice appear healthy without ob-
vious signs of a muscular dystrophy phenotype (15). However,
DUX4 overexpression by intramuscular injection with AAV6-
DUX4 in mouse skeletal muscle does lead to muscle damage
(16). In addition, a novel FSHD mouse model with muscle-
specific doxycycline-regulated DUX4 expression presents with a
slow progressive degenerative myopathy involving inflamma-
tion and fibrosis (17). The relatively low levels of DUX4 RNA and
protein in skeletal muscle in the D4Z4–2.5 mouse model may
explain the lack of muscle pathology in these mice.
Furthermore, DUX4 protein expression in D4Z4–2.5 mice is re-
stricted to Myog-negative myoblasts, which do not fuse into
myotubes (15). In contrast, in FSHD patients DUX4 protein ex-
pression is observed in myosin-positive myotubes (18,19). Thus,
the transgene spatial and temporal expression pattern may ex-
plain the failure of modelling the FSHD muscle phenotype in
our D4Z4–2.5 mice.
In the current study, we modelled the digenic requirements
of FSHD by crossbreeding D4Z4–2.5 mice with mice that are
haploinsufficient for Smchd1 (Smchd1MommeD1 mice), and we
evaluated the modifier role of Smchd1 on disease severity. The
Smchd1MommeD1 mutation, a nonsense Smchd1 mutation in
exon 23 (p.Q963X), was identified in an N-ethyl-N-nitrosourea
mutagenesis screen for modifiers of epigenetic reprogramming
(20). Smchd1 encodes a well-conserved protein with a C-terminal
SMC hinge domain and an N-terminal ATPase domain. In mice,
Smchd1 has roles in the establishment and/or maintenance of
DNA methylation, in X chromosome inactivation, and in the
regulation of some clustered and imprinted genes (21–23).
However, its exact function is still unknown. Smchd1MommeD1
homozygous females die between E9.5 and E11.5, and lack DNA
methylation at many X-linked genes, including Hprt1. In con-
trast, some homozygous males and all heterozygous males and
females survive, the latter presenting with normal Hprt1 DNA
methylation levels by adulthood (20,21).
In this study, we show that Smchd1 haploinsufficiency re-
sults in decreased Smchd1 transcript levels with consequences
for the chromatin structure of the D4Z4 transgene in the D4Z4–
2.5 mouse model. In addition, reduced Smchd1 expression
seems to affect specific tissues, most notably the skin and the
thymus. D4Z4–2.5/Smchd1MommeD1 mice present with signifi-
cantly increased DUX4 transcript levels in muzzle skin and thy-
mus leading to a skin phenotype starting from postnatal day 10
and a severely reduced body weight from postnatal day 12.
Similar, but much milder, skin lesions are also observed in
D4Z4–2.5 mice. This mouse model is not the first DUX4 express-
ing mouse model with a skin and a runting phenotype. The
iDUX4 (2.7) mouse carries a doxycycline-inducible DUX4 trans-
gene and presents with a skin phenotype consisting of in-
creased epidermal thickness and nuclear dermal density and
the carrier males that survived to birth were severely runted
(24). Importantly, Smchd1 haploinsufficiency does not seem to
impact skeletal muscle. DUX4 transcript levels are not or only
slightly increased in skeletal muscles of D4Z4–2.5/
Smchd1MommeD1 mice compared with D4Z4–2.5 mice. Also, the
skeletal muscles of the D4Z4–2.5/Smchd1MommeD1 mice do not
show overt muscle pathology. In conclusion, the D4Z4–2.5 mice
and the D4Z4–2.5/Smchd1MommeD1 mice can be used to study
the epigenetic regulation of the D4Z4 repeat array. Furthermore,
the D4Z4–2.5/Smchd1MommeD1 mouse model may be suitable to
study the function of DUX4 in the skin and the thymus.
Results
Smchd1 haploinsufficiency affects Smchd1 transcript
levels, D4Z4 chromatin structure, and potentially DUX4
expression
We showed previously that SMCHD1 binds the D4Z4 repeat in hu-
man fibroblast cultures (11). To determine whether mouse
Smchd1 binds the human D4Z4 transgene in the D4Z4–2.5 mouse
model, we performed Smchd1 chromatin immunoprecipitation
(ChIP) analysis in fibroblasts isolated from three neonatal D4Z4–
2.5 mice. This was indeed the case (Fig. 1A), and we concluded
that D4Z4–2.5 mice are a suitable model to evaluate the modifier
role of Smchd1 on D4Z4 chromatin structure, DUX4 expression,
and disease severity. Next, we determined the effect of the
Smchd1MommeD1 mutation on Smchd1 expression in D4Z4–2.5
mice by crossbreeding a heterozygous Smchd1MommeD1 male
mouse with a hemizygous D4Z4–2.5 female mouse. We then ob-
served that Smchd1 transcript levels were significantly reduced in
all tissues tested of hemizygous D4Z4–2.5 mice carrying
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Figure 1. Smchd1 haploinsufficiency affects Smchd1 transcript levels, D4Z4 chromatin structure, and potentially DUX4 expression. (A) Mouse Smchd1 binds the D4Z4
transgene in fibroblasts isolated from three neonatal D4Z4-2.5 mice, as tested by ChIP-qPCR analysis. (B) Relative Smchd1 expression in cerebellum, heart, quadriceps
muscle, and testis of D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 15). Statistical analysis was performed on the average Smchd1 expression in each
mouse using Student’s t-test (cerebellum, heart, quadriceps muscle) or Mann–Whitney U test (testis). *P<0.05; **P<0.01; ****P<0.0001. (C) DNA methylation levels were
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a heterozygous Smchd1MommeD1 mutation (D4Z4–2.5/
Smchd1MommeD1 mice) compared with hemizygous D4Z4–2.5
mice without the Smchd1MommeD1 mutation (Fig. 1B). Sanger se-
quencing showed that only Smchd1 transcripts from the wild-
type allele were present (data not shown). Thus, the mutant
Smchd1 transcript seems to be rapidly degraded in concordance
with a previous report (21). To determine the effect of the
Smchd1MommeD1 mutation on the chromatin structure of the
D4Z4 repeat, we measured DNA methylation at the region just
distal to the D4Z4 repeat (25). We found significantly reduced
DNA methylation levels at two CpG dinucleotides in DNA isolated
from the tails of D4Z4–2.5/Smchd1MommeD1 mice compared with
D4Z4–2.5 mice (Fig. 1C). We also detected a significantly lower
chromatin compaction score (ChCS; H3K9me3 level, a repressive
chromatin mark, corrected for H3K4me2 level, an active chroma-
tin mark) (26) in D4Z4–2.5/Smchd1MommeD1 mice when we per-
formed histone ChIP analysis using D4Z4-specific primers (9) in
fibroblasts isolated from D4Z4–2.5 and D4Z4–2.5/Smchd1MommeD1
neonates (Fig. 1D; P¼ 0.0108). Previously, we have shown that the
ChCS is significantly reduced in both fibroblasts and myoblasts of
FSHD patients compared with control individuals (26), which is
why we refrained from testing the ChCS in myoblasts of the
mice. Our results suggested that the Smchd1MommeD1 mutation
could potentially affect DUX4 transcript levels by modulating the
Figure 2. Genotype distribution, gender distribution, and body weight are distorted in mice born from D4Z4–2.5/Smchd1MommeD1 crossbreedings. (A) Genotype distribu-
tion is distorted in offspring of crossbred male heterozygous Smchd1MommeD1 mice and female hemizygous D4Z4-2.5 mice (tested at postnatal day 12). Statistical analy-
sis was performed using Pearson’s chi-squared test. P¼0.0054. (B) Gender distribution is distorted in offspring of crossbred male heterozygous Smchd1MommeD1 mice
and female hemizygous D4Z4-2.5 mice (tested at postnatal day 12). Statistical analysis was performed using Pearson’s chi-squared test. P¼0.0003. (C) The body weight
of D4Z4-2.5/Smchd1MommeD1 mice is significantly reduced at postnatal day 15 compared with the body weight of littermates. Statistical analysis was performed using
one-way ANOVA followed by Tukey post hoc test. ****P<0.0001. (D) The body weight of D4Z4-2.5/Smchd1MommeD1 mice from postnatal day 12 until postnatal day 22.
Seven mice lost body weight so quickly that they had to be euthanized on postnatal day 15; fourteen mice retained their body weight or gained some body weight from
12 days until 22 days of age. Black circles represent male mice; grey circles represent female mice. Each circle represents a single mouse (C, D).
measured at the region immediately distal to the D4Z4 repeat array in tail DNA of six D4Z4-2.5 (M1-M6) and six D4Z4-2.5/Smchd1MommeD1 (M7-M12) mice (postnatal
day 15). The bisulphite primers used amplify a region containing 10 CpG dinucleotides. Results are shown for 10 individual plasmid DNA samples per mouse. Open cir-
cles represent unmethylated CpG dinucleotides; closed circles represent methylated CpG dinucleotides. The bottom row shows the average DNA methylation level of
each CpG dinucleotide per genotype. Statistical analysis was performed using Student’s t-tests and multiple testing correction was performed by the Holm-Sidak
method. *P<0.05. (D) Relative chromatin compaction score (ChCS; H3K9me3 level corrected for H3K4me2 level) of the D4Z4 transgene in fibroblasts isolated from neo-
natal D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 2). Statistical analysis was performed using Student’s t-test.*P<0.05. (E) Relative DUX4 expression in
myoblast and myotube cultures generated from the EDL muscle of D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 15). No statistical analysis was per-
formed due to the low sample number. (F) Relative Mef2c expression (myogenic differentiation marker) in myoblast and myotube cultures generated from the EDL mus-
cle of D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 15). MB ¼ myoblast culture; MT ¼ myotube culture; 2.5 ¼ D4Z4-2.5 mouse; 2.5/SM ¼ D4Z4-2.5/
Smchd1MommeD1 mouse. No statistical analysis was performed due to the low sample number. Each bar represents a single mouse; error bars represent standard devia-
tions for technical replicates (A, B, D–F).
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Figure 3. Skeletal muscles of the D4Z4–2.5 mouse are relatively insensitive to reduced Smchd1 levels. (A) Relative DUX4 expression in four different skeletal muscles of
D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 15). Statistical analysis was performed on the average DUX4 expression in each mouse using Student’s
t-test (masseter muscle, quadriceps muscle) or Mann–Whitney U test (gastrocnemius muscle, TA muscle). ***P<0.001. (B) Representative H&E-stained cross sections
(20magnification) of quadriceps muscle and TA muscle of D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 15). (C) Western blot analysis of E12.5 embryo
lysates of the given genotype and sex (F ¼ female, M ¼male). The membrane was hybridised with two different Smchd1 antibodies, and compared with actin as a con-
trol. Smchd1 full-length protein is marked with a line. Smchd1Del/Del samples do not show detectable full-length Smchd1 with either Smchd1 antibody. (D) Expression
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chromatin structure of the D4Z4 transgene. We therefore ana-
lysed DUX4 expression in a small set of myoblast cultures gener-
ated from the extensor digitorum longus (EDL) muscles of
D4Z4–2.5 and D4Z4–2.5/Smchd1MommeD1 mice. DUX4 transcript
levels were highly increased in myotube cultures that were differ-
entiated for 48 h (differentiation was confirmed by measuring
Mef2c expression), and slightly increased in proliferating myo-
blast cultures of D4Z4–2.5/Smchd1MommeD1 mice compared with
D4Z4–2.5 mice (Fig. 1E and F). Thus, Smchd1 haploinsufficiency
potentially affects DUX4 expression.
Genotype distribution, gender distribution, and body
weight are distorted in mice born from D4Z4–2.5/
Smchd1MommeD1 crossbreedings
Because of the known role of Smchd1 in X chromosome inactiva-
tion (21), each crossbreeding pair in our study consisted of a male
Smchd1MommeD1 mouse and a female D4Z4–2.5 mouse, even
though adult heterozygous Smchd1MommeD1 females present with
normal Hprt1 DNA methylation levels (20,21). To date, approxi-
mately 300 pups born from D4Z4–2.5/Smchd1MommeD1
of the GFP3C transgene in 3-week-old mice hemizygous for the transgene, and Smchd1þ/þ (red line), Smchd1þ/fl (blue line) or Smchd1Del/þ (green line). Non-transgenic
mice were used as controls (orange line). Upper picture: Representative flow cytometry profiles. Lower picture: Percentage of GFP-expressing erythrocytes for all mice
tested. (E) Upper picture: Schematic of PCR analysis that was performed to detect floxed and deletion alleles in D4Z4-2.5/Smchd1CKO mice. Lower picture: Smchd1 dele-
tion in gastrocnemius muscle and myoblast cultures of D4Z4-2.5/Smchd1CKO mice. (F) Relative DUX4 expression in gastrocnemius muscle of D4Z4-2.5 and D4Z4-2.5/
Smchd1CKO mice. Statistical analysis was performed on the average DUX4 expression in each mouse using Student’s t-test. (G) Relative DUX4 expression in myoblast
cultures generated from the gastrocnemius muscle of D4Z4-2.5 and D4Z4-2.5/Smchd1CKO mice. No statistical analysis was performed due to the low sample number.
(H) Representative H&E-stained cross sections of gastrocnemius muscle of D4Z4-2.5 and D4Z4-2.5/Smchd1CKO mice (32 magnification). Each bar represents a single
mouse; error bars represent standard deviations for technical replicates (A, F, G).
Figure 4. D4Z4–2.5/Smchd1MommeD1 mice develop skin hyperkeratosis and alopecia at young age, while D4Z4–2.5 mice present with a mild skin phenotype at 9 weeks
of age. (A) Upper picture: A representative litter of pups born from crossbreeding a male heterozygous Smchd1MommeD1 mouse with a female hemizygous D4Z4-2.5
mouse (postnatal day 15). Lower picture: D4Z4-2.5/Smchd1MommeD1 mice show skin hyperkeratosis in the muzzle area (open arrow), on the eyelids, on the distal ends
of the limbs (closed arrow), and focal alopecia in the distal dorsal part of the trunk starting from postnatal day 10. (B) Representative longitudinal sections of complete
heads of the four different genotypes stained with H&E at postnatal day 15 (200magnification of the skin around the muzzle). The muzzle skin features of D4Z4-2.5/
Smchd1MommeD1 mice consist of extensive hyperkeratosis (asterisk), associated with thickening of the epidermis (blue line). (C) Representative longitudinal H&E
stained sections of complete heads of the four different genotypes showing the eyelid area at postnatal day 15 (100 magnification). The eyelids of D4Z4-2.5/
Smchd1MommeD1 mice show extensive hyperkeratosis (asterisk) with underlying keratitis (open arrow). The dermis shows an inflammatory infiltrate that is mostly
composed of lymphocytes and a minority of macrophages (black arrow). (D) Representative longitudinal sections of complete heads of control D4Z4-12.5 mice and
FSHD D4Z4-2.5 mice stained with H&E at 9 weeks of age (200magnification of the skin around the muzzle). The muzzle skin phenotype of D4Z4-2.5 mice consists of
mild hyperkeratosis (asterisk) that is visible from adulthood.
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crossbreedings have been genotyped. We found that at postnatal
day 12 the genotype distribution of the pups that were born from
these crossbreedings was significantly distorted (Fig. 2A;
P¼ 0.0054). This is probably because fewer D4Z4–2.5/
Smchd1MommeD1 mice were born, but more pups need to be geno-
typed to statistically confirm this hypothesis. In addition, less fe-
male mice were present at postnatal day 12 (Fig. 2B; P¼ 0.0003).
We furthermore observed that during the first days after birth the
D4Z4–2.5/Smchd1MommeD1 mice gained weight and were able to
feed, as evidenced by stomachs filled with milk. However, D4Z4–
2.5/Smchd1MommeD1 mice, both males and females, presented
with a runting phenotype; the mice were smaller and exhibited
an approximate 25% reduction in body weight compared with
their littermates at postnatal day 15, although there was consid-
erable variation in body weight reduction (Fig. 2C; P< 0.0001). We
followed a cohort of 21 D4Z4–2.5/Smchd1MommeD1 mice from post-
natal day 12 and found that 7 D4Z4–2.5/Smchd1MommeD1 mice (all
males) quickly lost body weight. These mice were therefore eu-
thanized at postnatal day 15. In contrast, the other 14 D4Z4–2.5/
Smchd1MommeD1 mice (10 males and 4 females) retained or gained
body weight from 12 days until 22 days of age (Fig. 2D). Due to the
large difference in body weight compared with littermates with
other genotypes, all remaining D4Z4–2.5/Smchd1MommeD1 mice
were euthanized at postnatal day 22. In conclusion, a non-
Mendelian inheritance pattern is observed for the pups born from
D4Z4–2.5/Smchd1MommeD1 crossbreedings, and D4Z4–2.5/
Smchd1MommeD1 mice are runted.
Skeletal muscles of the D4Z4–2.5 mouse are relatively
insensitive to reduced Smchd1 levels
We previously reported low and variable DUX4 expression in
skeletal muscles of D4Z4–2.5 mice (15). To determine whether
Smchd1 has a modifier role by regulating DUX4 expression
in vivo, we quantified DUX4 transcript levels in four different
skeletal muscles of D4Z4–2.5 and D4Z4–2.5/Smchd1MommeD1
mice [gastrocnemius muscle, masseter muscle, quadriceps
muscle, and tibialis anterior (TA) muscle]. DUX4 expression was
significantly increased in only one of the tested muscles of the
D4Z4–2.5/Smchd1MommeD1 mice compared with the D4Z4–2.5
mice, namely only in the quadriceps muscle (Fig. 3A; P¼ 0.0006).
In addition to the very low DUX4 transcript levels (Cq values
varied between 30 and 35), a possible explanation for this obser-
vation may be the prominent interindividual variability in DUX4
expression that we observed. In addition, the skeletal muscles
of D4Z4–2.5/Smchd1MommeD1 mice did not show overt skeletal
muscle pathology, as tested by haematoxylin and eosin (H&E)
staining of the quadriceps muscle and the TA muscle (Fig. 3B).
Therefore, we hypothesized that skeletal muscles of the D4Z4–
2.5 mouse are relatively insensitive to reduced Smchd1 levels.
To further address this hypothesis, we studied the D4Z4–2.5/
Smchd1CKO mouse model. This mouse model was generated by
crossbreeding the D4Z4–2.5 mouse model with mice that carry
exon 4 of Smchd1 floxed (Smchd1fl/fl mice) and express Cre
recombinase from the muscle-specific promoter Myf5 (27).
Smchd1fl/fl mice are viable and fertile, suggesting that the allele
is not hypomorphic. From heterozygous intercrosses between
Smchd1Del/þ mice [produced by crossbreeding Smchd1fl/fl mice
with a constitutive CMV-driven Cre recombinase mouse strain
(28)], no Smchd1Del/Del mice were observed at weaning (99 pups
were tested). This is consistent with the expected embryonic le-
thality of a null allele on the C57BL/6 background (21). Both
male (n¼ 8) and female (n¼ 5) Smchd1Del/Del embryos were
observed at E12.5 and loss of the Smchd1 protein in these em-
bryos was confirmed by Smchd1 western blot (Fig. 3C). However,
all females were very small, consistent with mid-gestation le-
thality as observed for other Smchd1 null alleles (21). As Smchd1
was first identified using a multicopy GFP transgene array, di-
rected to express in red blood cells (20,21), we also tested the ef-
fect of the floxed and deleted alleles on the expression of the
GFP3C transgene. We found no changes in expression with the
floxed allele, but an increased expression in Smchd1Del/þ mice
(Fig. 3D), confirming that the floxed allele behaves as a wild-
type allele and the deleted allele as a null allele.
In the D4Z4–2.5/Smchd1CKO mice we tested, the Smchd1 gene
was disrupted on both alleles in Myf5-positive cells (Fig. 3E).
DUX4 transcript levels were not significantly increased in the
complete gastrocnemius muscle (Fig. 3F), but we did measure in-
creased DUX4 expression in muscle cultures generated from the
gastrocnemius muscle (Fig. 3G), which is in line with our results
obtained in D4Z4–2.5/Smchd1MommeD1 mice. Furthermore, D4Z4–
2.5/Smchd1CKO mice presented with no additional phenotypes
compared with D4Z4–2.5 mice; also no muscular dystrophy phe-
notype was detected by H&E staining (Fig. 3H). Together, these
data indeed suggest that skeletal muscles of the D4Z4–2.5 mouse
are largely unaffected by reduced Smchd1 levels.
D4Z4–2.5/Smchd1MommeD1 mice develop skin
hyperkeratosis and alopecia at young age, while
D4Z4–2.5 mice present with a mild skin phenotype at
9 weeks of age
Besides the runting phenotype, D4Z4–2.5/Smchd1MommeD1 mice
developed alopecic and hyperkeratotic areas around the nose
(muzzle skin), on the dorsal aspect of all paws, and in approxi-
mately 10% of cases on the upper back of the trunk region, start-
ing at 10 days of age (Fig. 4A). The hyperkeratotic skin had a scaly
appearance. The skin lesions appeared in all mice and no gender
differences were observed. In addition, between postnatal days
11 and 14, when littermates started to open their eyes, the D4Z4–
2.5/Smchd1MommeD1 mice had difficulties opening their eyes
(Fig. 4A). Similar to the skin phenotype, the penetrance of this
phenotype was 100% and not gender-dependent. To gain more
insight into these phenotypes, we performed histopathological
examination of the mice at postnatal day 15. Serial sections of
complete heads of the D4Z4–2.5/Smchd1MommeD1 mice (n¼ 3) re-
vealed, particularly in the areas around the muzzle and the eye-
lids, thickening of the stratum corneum with increased layers of
keratin (orthokeratotic and parakeratotic hyperkeratosis), thick-
ening of the epidermis reaching 8–10 layers (epidermal hyperpla-
sia) with irregular rete ridges formations (downward projections
of the epidermis) (Fig. 4B), and minimal lymphocytic inflamma-
tion in the dermis (Fig. 4C). In contrast, histopathological investi-
gation of the complete heads of juvenile wild-type mice (n¼ 3),
Smchd1MommeD1 mice (n¼ 3), and D4Z4–2.5 mice (n¼ 3) was nor-
mal with no skin lesions apparent at 15 days of age (Fig. 4B
and C). Gross and histological examination of all organs revealed
no abnormalities for all four genotypes tested at postnatal day 15
(data not shown).
As shown previously, approximately 50% of D4Z4–2.5 mice
develop eye abnormalities, possibly due to incomplete closure
of the eyelids. The typical onset of the eye phenotype in D4Z4–
2.5 mice is around 8–12 weeks of age (15). In our current study,
histopathological examination did not reveal skin abnormalities
that could explain these eye abnormalities in D4Z4–2.5 mice at
postnatal day 15. To test whether D4Z4–2.5 mice develop a skin
722 | Human Molecular Genetics, 2018, Vol. 27, No. 4
Figure 5. Skin and thymus of the D4Z4–2.5 mouse are sensitive to Smchd1 haploinsufficiency. (A) Relative DUX4 expression in muzzle skin and thymus of D4Z4-2.5 and
D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 15). Statistical analysis was performed on the average DUX4 expression in each mouse using Student’s t-test (muzzle
skin) or Mann–Whitney U test (thymus). **P<0.01; ***P<0.001. (B) Relative DUX4 expression in cerebellum, heart, and testis of D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1
mice (postnatal day 15). Statistical analysis was performed on the average DUX4 expression in each mouse by Student’s t-test. (C) Relative Wfdc3 expression in muzzle
skin and thymus of D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 15). Statistical analysis was performed on the average Wfdc3 expression in each mouse
using Student’s t-test (muzzle skin) or Mann–Whitney U test (thymus). **P<0.01; ****P<0.0001. (D) Thymus weight (depicted as percentage of total body weight) of D4Z4-
2.5 and D4Z4-2.5/Smchd1MommeD1 mice (postnatal day 15). Statistical analysis was performed using Student’s t-test. The order of results is similar as in Figure 5A, thus
showing an inverse relationship between DUX4 expression and thymus weight. (E) Body weight of D4Z4-2.5/Smchd1MommeD1 mice at postnatal day 15. The mice are di-
vided into two groups; group 1 consisted of 5 mice that presented with relatively low DUX4 transcript levels in the thymus, while group 2 consisted of 3 mice with very
high DUX4 expression in the thymus. Statistical analysis was performed using Mann–Whitney U test. *P<0.05. Each bar represents a single mouse; error bars represent
standard deviations for technical replicates.
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phenotype in adulthood, we performed an additional histopath-
ological examination of complete heads at 9 weeks of age and
compared control D4Z4–12.5 mice (n¼ 3) with D4Z4–2.5 mice
(n¼ 3). A mild skin phenotype consisting of hyperkeratosis
was indeed observed around the muzzle and the eyelids of
D4Z4–2.5 mice, while no skin pathology was observed in the
D4Z4–12.5 mice (Fig. 4D). Thus, D4Z4–2.5 mice, like D4Z4–2.5/
Smchd1MommeD1 mice, present with eye and skin phenotypes.
However, these phenotypes develop earlier and are more severe
in D4Z4–2.5/Smchd1MommeD1 mice, as is expected from the hy-
pothesized modifier role of Smchd1 at the D4Z4 repeat array.
Skin and thymus of the D4Z4–2.5 mouse are sensitive to
Smchd1 haploinsufficiency
The phenotype of D4Z4–2.5/Smchd1MommeD1 mice seems re-
stricted to the body weight and the skin, with consequences for
the eyes. We therefore hypothesized that skin tissue is more sen-
sitive to Smchd1 haploinsufficiency and presents with higher
DUX4 transcript levels than skeletal muscles and other non-
skeletal muscle tissues. To test our hypothesis, we measured
DUX4 transcript levels in muzzle skin and in additional non-
skeletal muscle tissues, namely brain (cerebellum), heart, testis,
and thymus. Indeed, DUX4 expression was significantly increased
in the muzzle skin of D4Z4–2.5/Smchd1MommeD1 mice compared
with D4Z4–2.5 mice (Fig. 5A; P¼ 0.0004), whereas DUX4 transcript
levels in the cerebellum, heart, and testis were unchanged
(Fig. 5B). Unexpectedly, DUX4 expression was also significantly
increased in the thymus of D4Z4–2.5/Smchd1MommeD1 mice
(Fig. 5A; P¼ 0.0011). We also tested the expression of the DUX4
target gene Wfdc3 (15) in muzzle skin and thymus, and observed
a significant increase in Wfdc3 transcript levels in both tissues of
D4Z4–2.5/Smchd1MommeD1 mice (Fig. 5C; P< 0.01). Interestingly,
DUX4 expression in the thymus of D4Z4–2.5/Smchd1MommeD1
mice was highly variable. Of the eight mice tested, only three
D4Z4–2.5/Smchd1MommeD1 mice showed increased DUX4 expres-
sion in the thymus compared with D4Z4–2.5 mice. We found an
inverse relationship between the thymus weight and DUX4 ex-
pression in the thymus; the D4Z4–2.5/Smchd1MommeD1 mice with
the lowest thymus weight presented with the highest DUX4 tran-
script levels (Fig. 5A and D). We also observed that the body
weight of the D4Z4–2.5/Smchd1MommeD1 mice with the highest
DUX4 expression in the thymus was significantly reduced
compared with D4Z4–2.5/Smchd1MommeD1 mice with lower DUX4
transcript levels in the thymus (Fig. 5E; P¼ 0.0357). In conclusion,
our data indicate that, in contrast to the skeletal muscles and
some non-skeletal muscle tissues, skin and thymus are highly af-
fected by Smchd1 haploinsufficiency.
High DUX4 expression in the thymus of D4Z4–2.5/
Smchd1MommeD1 mice does not disturb intrathymic T
cell development
We found high DUX4 transcript levels in the thymus of D4Z4–
2.5/Smchd1MommeD1 mice (average Cq value of 22) and an in-
verse relationship between DUX4 expression in the thymus and
body weight. Therefore, we hypothesized that the runting phe-
notype observed in D4Z4–2.5/Smchd1MommeD1 mice is linked to
increased DUX4 expression in the thymus. Interestingly, mouse
Duxbl (also known as Duxl), whose homeodomains show 67%
identity to those of DUX4, was identified as a transcription fac-
tor with a critical role in the development of CD4/CD8 double-
negative (DN) mouse thymocytes (29–30). Normal expression
levels of Duxbl in the thymus stimulate the switch from
CD44high/CD25þ DN thymocytes to CD44low/CD25þ DN thymo-
cytes, while constitutive Duxbl expression disturbs the produc-
tion of CD4/CD8 double-positive (DP) thymocytes (29). We
performed flow cytometry analysis of the thymuses of wild-
type mice and D4Z4–2.5/Smchd1MommeD1 mice at postnatal day
15 to determine the percentage of DN thymocytes (subdivided
into DN1-DN4 thymocytes), DP thymyocytes, and single CD4
thymocytes and single CD8 thymocytes. Although the total
number of thymocytes in the D4Z4–2.5/Smchd1MommeD1 mice
was significantly reduced (data not shown), which was not sur-
prising because of the reduced thymus weight in some D4Z4–
2.5/Smchd1MommeD1 mice, the percentage of DN1, DN2, DN3,
and DN4 thymocytes and the percentage of DN, DP, CD4, and
CD8 thymocytes was not changed between wild-type mice and
D4Z4–2.5/Smchd1MommeD1 mice (Table 1). In addition, gross and
histological examination of the thymus of D4Z4–2.5/
Smchd1MommeD1 mice at postnatal day 15 appeared normal
(data not shown). Our data suggest that the development of thy-
mocytes in D4Z4–2.5/Smchd1MommeD1 mice is not blocked and
that it is unlikely that DUX4 interferes with Duxbl function as
an explanation for the thymus pathology.
Table 1. High DUX4 expression in the thymus of D4Z4–2.5/Smchd1MommeD1 mice does not disturb intrathymic development of thymocytes.
CD4 T cells and CD8 T cells develop in the thymus from bone marrow progenitors. In short, immature thymocyte progenitors [CD4/CD8 dou-
ble-negative (DN) cells] differentiate into CD4/CD8 double-positive (DP) cells to produce CD4 single-positive T cells or CD8 single-positive T
cells. To expand into the DP population, DN cells first undergo a developmental process consisting of 4 stages: DN1, DN2, DN3, and DN4 (29).
Average percentage of specific cell populations (6 standard deviation of biological replicates) in the thymus is shown for five wild-type (WT)
mice and four D4Z4–2.5/Smchd1MommeD1 mice. The percentage of DN cells, DP cells, CD4 cells, and CD8 cells is obtained from the total number
of cells in the thymus. The percentage of DN1 cells, DN2 cells, DN3 cells, and DN4 cells is obtained from the number of DN cells in the thymus.
Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak multiple comparison tests; the ratio of DN: DP: CD4: CD8
was compared between wild-type mice and D4Z4–2.5/Smchd1MommeD1 mice in one analysis, the ratio of DN1: DN2: DN3: DN4 was compared be-
tween wild-type mice and D4Z4–2.5/Smchd1MommeD1 mice in a second analysis.
Cell population Flow cytometry markers WT (% of cells) D4Z4–2.5/Smchd1MommeD1 (% of cells)
DN CD4()/CD8() 3.96 6 1.67 3.51 6 0.62
DP CD4(þ)/CD8(þ) 82.76 6 6.33 82.55 6 3.70
CD4 CD4(þ)/CD8(-) 8.11 6 0.78 7.96 6 0.77
CD8 CD4()/CD8(þ) 1.86 6 0.44 1.90 6 0.46
DN1 CD4()/CD8()/CD25()/CD44(þ) 14.70 6 3.35 15.38 6 0.78
DN2 CD4()/CD8()/CD25(þ)/CD44(þ) 10.90 6 4.03 11.68 6 3.19
DN3 CD4()/CD8()/CD25(þ)/CD44() 17.87 6 11.59 12.87 6 7.95
DN4 CD4()/CD8()/CD25()/CD44() 56.56 6 17.93 60.10 6 11.52
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DUX4 is highly expressed in keratinocytes
To determine what cell type in muzzle skin expresses DUX4, we
isolated total skin from D4Z4–2.5 and D4Z4–2.5/Smchd1MommeD1
neonates and separated dermis and epidermis to isolate fibro-
blasts and keratinocytes, respectively. Interestingly, DUX4
transcript levels were very high in keratinocytes (Cq values
around 26 in proliferating keratinocytes; Cq values around 24 in
keratinocytes that were differentiated for 7 days), while DUX4
expression in fibroblasts was low (Cq values around 33). We also
observed higher DUX4 transcript levels in fibroblasts,
Figure 6. DUX4 is highly expressed in keratinocytes of D4Z4–2.5/Smchd1MommeD1 mice. (A) Relative DUX4 expression in fibroblasts, proliferating keratinocytes, and ker-
atinocytes that were differentiated for 7 days generated from skin of D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice. No statistical analysis was performed due to low
sample number. (B) Relative keratin 14 (Krt14) and transglutaminase 1 (Tgm1) expression in the muzzle skin of D4Z4-2.5 and D4Z4-2.5/Smchd1MommeD1 mice.
Statistical analysis was performed on the average expression in each mouse using Student’s t-test (Tgm1) or Mann–Whitney U test (Krt14). *P<0.05. (C) Representative
longitudinal sections of the muzzle skin of wild-type, D4Z4-2.5, and D4Z4-2.5/Smchd1MommeD1 mice stained with DAPI and DUX4 at postnatal day 15 (20x magnifica-
tion). An example of a DUX4-positive cell in the epidermal cell layer of the muzzle skin of a D4Z4-2.5/Smchd1MommeD1 mouse is marked with an asterisk. Each bar rep-
resents a single mouse; error bars represent standard deviations for technical replicates (A, B).
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proliferating keratinocytes, and differentiated keratinocytes of
D4Z4–2.5/Smchd1MommeD1 mice compared with D4Z4–2.5 mice
(Fig. 6A). We next tested the transcript levels of two keratino-
cyte differentiation markers, keratin 14 (Krt14) and transgluta-
minase 1 (Tgm1), in the muzzle skin of D4Z4–2.5 and D4Z4–2.5/
Smchd1MommeD1 mice. We detected increased transcript levels
for both markers in the muzzle skin of D4Z4–2.5/
Smchd1MommeD1 mice compared with D4Z4–2.5 mice (Fig. 6B;
P< 0.05). Finally, we tested DUX4 protein in the muzzle skin of
the mice by immunofluorescence staining of muzzle skin sec-
tions. So far, we and others have not been able to detect DUX4
protein in tissues of the D4Z4–2.5 mouse. This is most likely due
to low DUX4 transcript levels in combination with the lack of a
sensitive assay to detect DUX4 protein. Only after isolating mus-
cle fibres from the EDL muscle and generating myotube cul-
tures, DUX4 protein could be detected in sporadic muscle nuclei
(15). As DUX4 transcript levels are high in the muzzle skin of
D4Z4–2.5/Smchd1MommeD1 mice, we expected that we could de-
tect DUX4 protein by immunofluorescence staining. Indeed, we
found that the epidermal cell layer of muzzle skin, mainly con-
sisting of keratinocytes, of D4Z4–2.5/Smchd1MommeD1 mice
expresses DUX4 protein (Fig. 6C). In contrast, we did not detect
appreciable DUX4 protein in muzzle skin of wild-type and
D4Z4–2.5 mice, even though DUX4 transcript levels were also
relatively high in the muzzle skin of D4Z4–2.5 mice. Our results
suggest that high DUX4 expression in combination with re-
duced Smchd1 levels in the skin may affect the keratinization
process in mice.
Discussion
Previously, we described the D4Z4–2.5 mouse model that carries
an FSHD-sized D4Z4 repeat array of 2.5 units. Although these
transgenic mice can be used to study the in vivo epigenetic regu-
lation of the D4Z4 repeat array locus, the expression of DUX4 in
skeletal muscles is low and no muscular dystrophy phenotype
has been observed (15). Interestingly, variants in SMCHD1 have
not only been identified in FSHD2 patients, but also in FSHD1
patients. FSHD patients with both a contracted D4Z4 repeat ar-
ray and a SMCHD1 mutation present with an unusually high
clinical severity and potentially higher DUX4 transcript levels in
skeletal muscles as suggested by SMCHD1 knockdown experi-
ments in FSHD1 myotube cultures (13). By crossbreeding
hemizygous D4Z4–2.5 female mice with heterozygous
Smchd1MommeD1 male mice (20), we expected to detect in-
creased DUX4 expression in skeletal muscles of D4Z4–2.5/
Smchd1MommeD1 mice, and possibly muscle pathology.
The analysis of Smchd1 transcript levels in a diverse set of tis-
sues revealed reduced Smchd1 expression in mice carrying the
Smchd1MommeD1 mutation. In addition, we found reduced DNA
methylation levels in the region immediately distal to the D4Z4
repeat array and a more open chromatin structure at the D4Z4 re-
peat array, as measured by the chromatin compaction score
(H3K9me3 level corrected for H3K4me2 level). However, only two
CpG dinucleotides in the region distal to the D4Z4 repeat array
(25) were differentially methylated between D4Z4–2.5 and D4Z4–
2.5/Smchd1MommeD1 mice. It will be interesting to determine why
specific CpG dinucleotides seem more sensitive to the presence
of the Smchd1MommeD1 mutation. This may provide insight in the
epigenetic regulation of the D4Z4 repeat array locus by SMCHD1,
as it is currently unknown how SMCHD1 exactly affects the chro-
matin structure of the D4Z4 repeat array. The advantage of using
the D4Z4–2.5 and D4Z4–2.5/Smchd1MommeD1 mouse models for
such studies is that the mouse genome, unlike the human
genome, does not contain D4Z4-like repeat units scattered
throughout the genome. Furthermore, our data show that the
epigenetic regulation of the D4Z4 transgene in D4Z4–2.5 and
D4Z4–2.5/Smchd1MommeD1 mice parallels the epigenetic regula-
tion observed in humans (15).
We observed that the genotype distribution was distorted on
postnatal day 12 when crossbreeding a male heterozygous
Smchd1MommeD1 mouse with a female hemizygous D4Z4–2.5
mouse. Our data suggest that fewer D4Z4–2.5/Smchd1MommeD1
are born from such crossbreedings. However, additional pups
need to be genotyped to confirm this observation. We did not
genotype pups before postnatal day 12 as we did not want to
disturb the nest. Therefore, some D4Z4–2.5/Smchd1MommeD1
pups may have died between birth and 12 days of age, although
we did not often observe dead pups in the cages. Alternatively,
D4Z4–2.5/Smchd1MommeD1 mice may have died during embryo-
genesis, and this is currently under study. It will be interesting
to analyse offspring from reciprocal crosses, since Smchd1 has
a role in X chromosome inactivation (21).
The analysis of DUX4 transcript levels in a set of skeletal
muscles, and in myoblast and myotube cultures generated from
the EDL muscle, showed us that DUX4 expression is potentially
increased in skeletal muscles of D4Z4–2.5/Smchd1MommeD1 mice
compared with D4Z4–2.5 mice. However, DUX4 transcript levels
in skeletal muscles of D4Z4–2.5/Smchd1MommeD1 mice were very
low and we observed high interindividual variability in DUX4
expression. Furthermore, we did not observe muscle pathology
in skeletal muscles of D4Z4–2.5/Smchd1MommeD1 mice nor in
skeletal muscles of D4Z4–2.5/Smchd1CKO mice. Therefore, we
believe that skeletal muscles of D4Z4–2.5 mice are relatively in-
sensitive to reduced Smchd1 levels. Alternatively, high DUX4
RNA and protein expression may only be measured in this
mouse model during skeletal muscle regeneration. We recently
showed that intramuscular cardiotoxin injections resulting in
severe muscle damage and skeletal muscle regeneration were
associated with significantly transient increased DUX4 tran-
script levels in the D4Z4–2.5 mouse model during early muscle
regeneration (31). Due to the severe phenotype of D4Z4–2.5/
Smchd1MommeD1 mice, we have refrained from performing simi-
lar experiments in these mice. However, it would be interesting
to determine how Smchd1 haploinsufficiency affects DUX4 ex-
pression during in vivo skeletal muscle regeneration. Finally, our
previous studies showed that DUX4 protein expression in D4Z4–
2.5 mice is restricted to Myog-negative myoblasts; these cells do
not fuse into myotubes (15). This contrasts with DUX4 protein
expression in human myoblasts where DUX4-positive cells are
typically myosin-positive and thus part of fused myotubes
(18,19). A mouse model with DUX4 protein expression in
myosin-positive cells may thus respond differently to Smchd1
haploinsufficiency in skeletal muscles, and may serve as a bet-
ter model to study the modifier role of Smchd1 in the muscle
phenotype. For example, a novel mouse model with muscle-
specific doxycycline-regulated DUX4 expression that was re-
cently generated presents with DUX4-positive nuclei sur-
rounded by myosin heavy chain-positive cytoplasm (17).
Unfortunately, this mouse model lacks a D4Z4 repeat array to
which Smchd1 can bind and thus cannot be used to study
Smchd1 haploinsufficiency in skeletal muscles.
In contrast to what we observed in skeletal muscles,
Smchd1 haploinsufficiency impacts the skin and thymus of
D4Z4–2.5 mice. We detected increased DUX4 transcript levels in
muzzle skin and primary fibroblasts and keratinocytes isolated
from D4Z4–2.5/Smchd1MommeD1 mice. In addition, D4Z4–2.5/
Smchd1MommeD1 mice presented with a severe skin phenotype
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starting from postnatal day 10, especially around the muzzle
and on the paws. The eyelids were also affected as shown by
histopathological examination and D4Z4–2.5/Smchd1MommeD1
mice had difficulties opening their eyes. These data give us the
opportunity to explain the uncharacterized eye phenotype that
was previously described for D4Z4–2.5 mice (15), since a similar,
albeit milder, skin phenotype was detected in D4Z4–2.5 mice at
9 weeks of age. Furthermore, we detected increased DUX4 ex-
pression in the thymus of D4Z4–2.5/Smchd1MommeD1 mice.
Interestingly, not all D4Z4–2.5/Smchd1MommeD1 mice presented
with higher thymic DUX4 transcript levels than D4Z4–2.5 mice,
and we identified an inverse relationship between DUX4 ex-
pression in the thymus and body weight. In addition, the D4Z4–
2.5/Smchd1MommeD1 mice with very high thymic DUX4 tran-
script levels lost body weight so rapidly from postnatal day 12
that they had to be euthanized on postnatal day 15, while the
body weight of the D4Z4–2.5/Smchd1MommeD1 mice with lower
DUX4 expression in the thymus was still increasing at postnatal
day 15. It is interesting that D4Z4–2.5/Smchd1MommeD1 mice
show skin and runting phenotypes, as this is not the first DUX4
expressing mouse model with these phenotypes. A mouse
model carrying a doxycycline-inducible transgene that encodes
DUX4 and 3’ genomic DNA, integrated into the mouse X chro-
mosome, displays a variety of phenotypes including increased
epidermal thickness and nuclear density in the dermis, and re-
duced body weight (24). In addition, a recent study of these
iDUX4(2.7) mice showed that females are hyperactive and have
significantly impaired hearing loss at high frequencies, while
males show periods of increased respiration and catatonic tor-
por (32). We have not yet investigated these non-skeletal mus-
cle phenotypes in D4Z4–2.5/Smchd1MommeD1 mice, but it may be
worthwhile to study this in more detail because of the overlap
in skin and runting phenotypes between the iDUX4(2.7) mouse
model and the D4Z4–2.5/Smchd1MommeD1 mouse model.
Overall, we conclude that haploinsufficiency for Smchd1 exac-
erbates the phenotype of the D4Z4–2.5 mouse model. However,
the phenotype of D4Z4–2.5/Smchd1MommeD1 mice is still re-
stricted to specific tissues, as was already observed in the
D4Z4–2.5 mouse (15).
This study shows that Smchd1 haploinsufficiency aggra-
vates the phenotype of the D4Z4–2.5 mouse model, a transgenic
mouse model for FSHD1. Notably, our data reveal that the skin
and the thymus of this mouse model are very sensitive to re-
duced Smchd1 levels, while skeletal muscles seem unaffected.
To study muscle pathology associated with FSHD, other mouse
models will need to be studied, such as the recently generated
mouse model with muscle-specific doxycycline-regulated DUX4
expression (17). However, our study provides support that the
D4Z4–2.5 mouse model can be used to study the epigenetic reg-
ulation of the D4Z4 repeat array. In addition, the D4Z4–2.5/
Smchd1MommeD1 mouse model may be ideal to study the func-
tion of DUX4 in the epidermis and the thymus. Interestingly,
DUX4 expression was recently reported in human skin and con-
fluent keratinocytes. ChIP sequencing analysis showed that re-
pressive H3K9me3 levels at the D4Z4 repeat array, both at
chromosome 4q35 and chromosome 10q26, dropped signifi-
cantly during confluence-induced squamous differentiation.
Western blot analysis and immunohistochemistry detected
DUX4 protein in keratinocytes in the epidermis of a control indi-
vidual, and the full-length DUX4 transcript was also detected in
confluent keratinocytes (33). Another study reported DUX4 ex-
pression, together with expression of the DUX4 target genes
TRIM43 and MBD3L2, in human thymus (34). In conclusion,
DUX4 may have a function outside the germline.
Materials and Methods
D4Z4–2.5/Smchd1MommeD1 mice
D4Z4–2.5 mice and Smchd1MommeD1 mice were generated previ-
ously (15,20). All D4Z4–2.5/Smchd1MommeD1 mice were obtained
by crossbreeding a male heterozygous Smchd1MommeD1 mouse
with a female hemizygous D4Z4–2.5 mouse. Resulting offspring
were genotyped by PCR analysis using tail DNA. The D4Z4–2.5
transgene was detected by PCR using the following primers: 5’-
TGGTCCGTGAAGACATGTGT-3’ and 5’- GAGCCCTCAGAGAAGT
GGG-3’. The Smchd1MommeD1 mutation was detected by PCR
with the following primers: 5’-CAATAGGTCCCCCTCATCAA-3’
and 5’-CAGTGGCCAACCACATAACA-3’. An internal probe with
the sequence 5’-CAACATAACAGCACAACCAAAGCTG-3’ was
added to the PCR mixture so that after the reaction the PCR
product could be melted by Lightscanner (Idaho Technology
Inc., Salt Lake City, USA) resulting in different melt curves for al-
leles with the Smchd1MommeD1 mutation and for alleles without
the Smchd1MommeD1 mutation. Wild-type mice, Smchd1MommeD1
mice, and D4Z4–2.5 mice of the same genetic background as the
D4Z4–2.5/Smchd1MommeD1 mice were used as controls. All mice
were bred at the animal facility of the Leiden University Medical
Center. Mice were housed in individually ventilated cages with
a standard 12h/12h light/dark cycle. Standard rodent chow and
water were available ad libitum. All experiments were approved
by the Animal Experiments Committee of the LUMC.
Smchd1fl/fl mice and Smchd1Del/þmice
A Smchd1 targeting construct that introduced loxP sites sur-
rounding exon 4 of Smchd1 and a neomycin cassette flanked by
Frt sites was produced by recombineering. The targeting con-
struct was electroporated into Bruce4 C57BL/6 embryonic stem
cells. Neomycin-resistant clones were screened by Southern
blot for their integrations at the 5’ and 3’ ends, using PCR ampli-
fied probes (5’-probe amplified with 5’-CTAAGCCCAGAACCTTG
CAC-3’ and 5’-CTTGAAAGCAGACAGGCTCA-3’; 3’-probe ampli-
fied with 5’-GCCCATTATTCCTCCAAACA-3’ and 5’-GAATTTGCA
TTTGGAAAGGA; each probe was cloned into a TOPO TA vector).
The DNA was then cut with BssSI for the 5’-probe, and with
BssSI, BglII, NcoI, and KpnI for the 3’-probe. One correctly tar-
geted clone was used to produce mice by blastocyst injection.
The neomycin cassette was removed by crossing with the
Rosa26-FLPe knockin mouse strain (35). The Smchd1fl allele was
maintained on a C57BL/6 background. The Smchd1Del allele was
generated by crossing with a constitutive CMV-driven Cre
recombinase mouse strain (28), and was also maintained on a
C57BL/6 background. All mice were produced and maintained
under approval by The Walter and Eliza Hall Institute of Medical
Research Animal Ethics Committee (AEC 2014.026).
D4Z4–2.5/Smchd1CKO mice
Mice expressing Cre recombinase from the muscle-specific Myf5
locus have been described previously (27). The Smchd1 condi-
tional knock-out line (Smchd1fl/fl mice) is described above.
Progeny positive for the D4Z4–2.5 transgene, hemizygous or
negative for Myf5-Cre recombinase, and homozygous for floxed
Smchd1 were produced by a series of crossbreedings and identi-
fied by PCR analysis using toe DNA. Myf5-Cre recombinase was
detected by PCR with the following primers: 5’-CGTAGAG
CGCTGAAGAAGGTCAAC-3’ (MyfkI forward), 5’-CACATTAGAAA
ACCTGCCAACACC-3’ (MyfkI reverse), and 5’-ACGAAGTTAT
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TAGGTCCCTCGAC-3’ (Lox). Floxed Smchd1 alleles were detected
by PCR with the following primers: 5’-CCATGAGAAGCAAT
GTGGGA-3’ (F4) and 5’- GGACAGCCAAAGTGACACAG-3’ (R1).
The D4Z4–2.5 transgene was detected by PCR with the following
primers: 5’-CGGAGAACTGCCATTCTTTC-3’ (LS 352F) and 5’-
CAGCCAGAATTTCACGGAAG-3’ (LS 354R). Cre-dependent dele-
tion of sequences from the Smchd1 locus was confirmed by PCR
analysis of genomic DNA isolated from gastrocnemius muscle
with the following primers: 5’-TCAGGTGGTCTCGAGCCC-3’ (F2)
and 5’-GGACAGCCAAAGTGACACAG-3’ (R1). The intact Smchd1
allele was detected by PCR using the following primers: 5’-
TCAGGTGGTCTCGAGCCC-3’ (F2) and 5’-TCGAGAAGTAGCTGA
CAATGAA-3’(R2). A single Myf5-cre allele was shown to be suffi-
cient for deletion of the Smchd1 floxed region, and we did not
observe gender-dependent or age-dependent differences in the
phenotype of animals positive or negative for the Cre insertion.
All mice were bred at the animal facility of the Fred Hutchinson
Cancer Research Center and maintained in accordance with the
NIH Guide for the Care and Use of Experimental Animals. All ex-
periments were approved by the Institutional Animal Care and
Use Committee of the Fred Hutchinson Cancer Research Center.
Isolation and culturing of neonatal fibroblasts and
keratinocytes
Neonatal mice were euthanized by decapitation followed by re-
moval of the complete skin. Primary fibroblasts and primary
keratinocytes were isolated following the protocol supplied by
the manufacturer (CELLnTEC; Bioconnect, Huissen, the
Netherlands). In short, the skin of the mice was removed, fol-
lowed by overnight incubation in a dispase solution containing
antibiotics and antimycotics (CELLnTEC; Bioconnect, Huissen,
the Netherlands). The next day, the epidermis and dermis were
separated using forceps. The dermis was next cut into small
pieces and distributed over a 60 mm dish with addition of a
small amount of DMEM/F12 medium (Thermo Fisher Scientific,
Bleiswijk, the Netherlands) supplemented with 1% penicillin–
streptomycin (Sigma Aldrich, Zwijndrecht, the Netherlands)
and 20% heat-inactivated foetal bovine serum (Thermo Fisher
Scientific, Bleiswijk, the Netherlands). Over the course of the
week, primary fibroblasts grew out of the dermis pieces. Upon
confluence, the cells were transferred to a 100 mm dish and the
dermis pieces were discarded. The epidermis was incubated for
20–30 min at room temperature in Accutase (CELLnTEC;
Bioconnect, Huissen, the Netherlands). After this incubation
step, the epidermis was gently rubbed in a 60 mm dish to obtain
single cells. These cells were then centrifuged for 5 min at room
temperature and seeded at a density of 4104 cells/cm2 in a 6-
well plate containing CnT-PR medium (CELLnTEC; Bioconnect,
Huissen, the Netherlands). One day before confluence, cells
were either harvested (proliferating keratinocytes) or the me-
dium was changed to CnT-PR-D medium (CELLnTEC;
Bioconnect, Huissen, the Netherlands). At confluence, 1.2 mM
Ca2þ was added to the medium to drive differentiation.
Differentiated keratinocytes were harvested 7 days after chang-
ing the medium to CnT-PR-D medium.
Isolation and culturing of EDL single muscle fibres
Mice were euthanized by cervical dislocation followed by dis-
section of the EDL muscle from tendon to tendon. Next, the EDL
muscle was digested twice in 0.2% collagenase (Sigma Aldrich,
Zwijndrecht, the Netherlands) in DMEM medium (Thermo
Fisher Scientific, Bleiswijk, the Netherlands) supplemented with
1% penicillin-streptomycin (Sigma Aldrich, Zwijndrecht, the
Netherlands) at 37C for 105 and 120 min, respectively. The re-
sulting fibres were dissociated using Pasteur pipettes with dif-
ferent apertures, followed by several washing steps as
described previously (36). Next, 150 individual fibres were cul-
tured on matrigel-coated (BD, Breda, the Netherlands) 6-well
plates in DMEM medium supplemented with 30% foetal bovine
serum, 10% horse serum, 1% penicillin-streptomycin, 1%
chicken embryo extract, and 2.5 ng/ml fibroblast growth factor
(all Thermo Fisher Scientific, Bleiswijk, the Netherlands). The fi-
bres were detached and removed after 3 days. The attached
myoblasts were trypsinised, counted, and plated for experi-
ments. Differentiation of myoblasts into myotubes was induced
after 48 h by replacing the original medium with DMEM medium
supplemented with 2% horse serum and 1% penicillin-
streptomycin (both Thermo Fisher Scientific, Bleiswijk, the
Netherlands). At the same time, myoblasts were harvested. 48 h
post-differentiation, myotubes were harvested.
Quantitative DNA methylation analysis by bisulphite
conversion sequencing
Bisulphite treatment was performed on 400 ng of genomic DNA
isolated from mouse tail and we used the EZ DNA Methylation-
Lightning kit (Zymo Research; BaseClear Lab Products, Leiden,
the Netherlands). DNA methylation levels of the D4Z4–2.5 trans-
gene were quantified by PCR analysis using the following pri-
mers: 5’-ATAGGGAGGGGGTATTTTA-3’ and 5’-ACRATCAAAAAC
ATACCTCTATCTA-3’ (25). Next, the PCR product was ligated
into the TOPO TA vector (Thermo Fischer Scientific, Bleiswijk,
the Netherlands), followed by transformation of the ligation
product in DH5a bacteria, and Sanger sequencing of plasmid
DNA isolated from individual colonies. 10 individual colonies
Table 2. List of RT-PCR primers and corresponding sequences
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were picked for each DNA sample and sent for Sanger
sequencing.
Smchd1 and histone ChIP analyses
We followed a previously published protocol with minor modifi-
cations (37). In short, confluent cultures of neonatal fibroblasts
(three 150 mm plates) were crosslinked in 1% formaldehyde for
10 min at room temperature followed by quenching of the reac-
tion with 125 mM glycine for 5 min at room temperature. Next,
crosslinked cells were lysed in NP buffer [150 mM NaCl, 50 mM
Tris-HCl (pH 7.5), 5 mM EDTA, 0.5% NP-40, 0.1% Triton X-100] and
the resulting chromatin was sheared using a sonicator bath
(Bioruptor Pico; Diagenode, Ougrée, Belgium) for 30 min at maxi-
mum output and 30 s on/off cycles. Shearing of DNA fragments
between 200–2000 bp was confirmed through phenol-chloroform
extraction and agarose gel electrophoresis. DNA concentrations
were determined with a Nanodrop ND-1000 spectrophotometer
(Thermo Fisher Scientific, Bleiswijk, the Netherlands). For
Smchd1 ChIP analysis, 30 mg of chromatin was first precleared for
1 h with blocked protein A Sepharose beads (GE Healthcare,
Eindhoven, The Netherlands) followed by overnight incubation
with a Smchd1 antibody (5 mg of ab31865; Abcam, Cambridge,
United Kingdom) or with mouse IgG (5 mg; Diagenode, Ougrée,
Belgium). For histone ChIP analysis, 3 mg of chromatin was pre-
cleared and we used the following antibodies: H3K4me2 (5 mg of
39141; Active Motif, Carlsbad, USA), H3K9me3 (5 mg of 39161;
Active Motif, Carlsbad, USA), and mouse IgG (5 mg; Diagenode,
Ougrée, Belgium). Immunoprecipitation was performed with 20 ml
blocked sepharose A beads per reaction, and washing was per-
formed according to the previously published protocol (37).
Finally, DNA was isolated using Chelex resin (Bio-Rad,
Veenendaal, the Netherlands) and diluted 1: 1 for quantitative
analysis by RT-PCR. We used the following primers to amplify
the D4Z4 repeat array: 5’- CCGCGTCCGTCCGTGAAA-3’ and
5’-TCCGTCGCCGTCCTCGTC-3’ (9).
RNA isolation and cDNA synthesis
Total RNA was isolated from different mouse tissues and cells
using the miRNeasy kit (Qiagen, Venlo, the Netherlands) accord-
ing to the manufacturer’s instructions and included a DNase
treatment. RNA concentrations were determined with a
Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific, Bleiswijk, the Netherlands). 1–3 lg of total RNA was
reverse transcribed using the RevertAid H Minus First Strand
cDNA synthesis kit with Oligo(dT)18 primers (both Thermo
Fisher Scientific, Bleiswijk, the Netherlands), according to the
instructions of the manufacturer. The resulting cDNA was
treated with 2 units of RNaseH (Thermo Fisher Scientific,
Bleiswijk, the Netherlands) at 37C for 20 min and diluted in
100 ll H2O. 2–5 ll of the diluted cDNA was used for quantitative
RT-PCR analysis.
Quantitative RT-PCR analysis
RT-PCR analysis was performed in duplicate using the CFX96
system (Bio-Rad, Veenendaal, the Netherlands) with SYBR green
mastermix and 0.5 pM of each primer in a 15 ll final reaction
volume. All primers, spanning at least one intron, were de-
signed using Primer3 software. Primer sequences for all reac-
tions are listed in Table 2. The following cycling conditions were
used: an initial denaturation step at 95C for 3 min followed by
40 cycles of 10 s at 95C and 45 s at primer Tm. Next, a melting
curve analysis was performed to determine the specificity of all
reactions. This analysis consisted of an initial denaturation step
at 95C for 3 min followed by 1 min incubation step at 65C and
sequential temperature increments of 0.5C from 65–95C.
Results were analysed with Bio-Rad CFX Manager version 3.1
(Bio-Rad, Veenendaal, the Netherlands) and normalized to the
reference gene Rpl27 (Fig. 3F and G) or to the reference genes
Gapdh and Rpl13a (all other figures) to correct for cDNA input.
Flow cytometry of the GFP3C transgene
Mice were tailed at three weeks of age and a drop of blood was
diluted in PBS. Flow cytometry was next performed to analyse
GFP expression in red blood cells (20). All mice analysed were
hemizygous for the GFP3C transgene, and the GFP3C line of
mice has been backcrossed for more than 10 generations from
FVB/N background to C57BL/6 background.
Smchd1 Western blot
Whole E12.5 embryos were harvested from intercrosses be-
tween Smchd1Del/þ mice. Embryo tail DNA was used for geno-
typing. Embryos were lysed and prepared for western blot as
described previously (38). Smchd1 was detected with two differ-
ent Smchd1 antibodies (Bethyl labs A302–871A at 1/2000 dilu-
tion or Abcam ab31865 at 1/2000 dilution). An actin antibody
was included as a control (Santa Cruz sc1616 at 1/1000 dilution).
H&E staining of skeletal muscles
Skeletal muscles were dissected and frozen in isopentane
cooled to165C. Next, five-micron cryosections were cut, fol-
lowed by H&E staining consisting of a 5 min incubation in hae-
matoxylin, 1 min incubation in eosin, and several washing
steps with dH2O, ethyl alcohol, and xylene. H&E-stained sec-
tions were analysed by light microscopy (Leica Microsystems
B.V., Rijswijk, the Netherlands).
DUX4 staining of muzzle skin
Muzzle skins were dissected and frozen in isopentane cooled
to165C. Cryosections were cut at 5 mm thickness and placed
on Superfrost Plus glasses (Thermo Fisher Scientific, Bleiswijk,
the Netherlands). The sections were fixed with 4% formalde-
hyde in PBS for 10 min at room temperature and washed three
times in PBS/0.5% Tween for 5 min. Next, the samples were
blocked with 10% normal goat serum (Agilent, Amstelveen, the
Netherlands) for 30 min and incubated with primary rabbit
DUX4 antibody directed against the C-terminal region of DUX4
(E5.5; 1: 300 in PBS/0.1% BSA) (39). After a triple wash in PBS/0.5%
Tween for 3 min, Alexa 488 donkey anti-rabbit (Thermo Fisher
Scientific, Bleiswijk, the Netherlands; diluted 1: 100 in PBS/
0.1%BSA) was applied for 30 min in the dark. The excess was re-
moved by a triple PBS/0.5% Tween wash. Finally, the sections
were incubated with PBS/dapi (500 ng/ml) for 15 min in the
dark, washed 3 min with PBS/0.5% Tween and mounted with
Aqua Poly/Mount (Polysciences Europe GmbH, Hirschberg an
der Bergstrasse, Germany). The stained sections were analysed
on a Leica DMRA2 microscope (Leica Microsystems B.V.,
Rijswijk, the Netherlands).
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Histopathological examination
Complete necropsy was performed on mice that were 15 days or
9 weeks of age. Next, tissues were fixed in 4% neutral buffered
formalin, and bone tissues were subjected to an additional de-
calcification step by incubation in formic acid for 5 days.
Successively, all tissues were embedded in paraffin, sectioned
at five micron, stained with H&E, and evaluated by light micros-
copy following standard procedures (40,41).
Flow cytometry of thymocytes
Single cell suspensions of thymocytes were obtained by homog-
enization of the thymus over 70 lm strainers (VWR
International B.V., Amsterdam, the Netherlands). Cells were
washed with phosphate-buffered saline containing 2% foetal
bovine serum and subsequently stained with aCD8a-Efluor450,
aCD4-PerCP-Cy5.5, aCD25-PE and aCD44-APC (all Thermo Fisher
Scientific, Bleiswijk, the Netherlands) for 20 min at 4C. After an
additional washing step, flow cytometry was performed on a
Canto II instrument (Becton Dickinson B.V., Vianen, the
Netherlands) and analysed using FlowJo software (Becton
Dickinson B.V., Vianen, the Netherlands).
Statistical analysis
Statistical analysis was performed using GraphPad Prism soft-
ware (version 7.00; GraphPad Software, Inc., La Jolla, USA). Most
data sets were compared using unpaired Student’s t-tests or
Mann–Whitney U tests, depending on whether the data were
normally distributed (normality was determined by Shapiro-
Wilk normality tests). The D4Z4 DNA methylation levels were
compared using Student’s t-tests; multiple testing correction
was performed by Holm-Sidak multiple comparison tests.
Genotype and gender distribution was tested by Pearson’s chi-
squared test. Body weight was tested by one-way analysis of
variance (ANOVA) followed by Tukey post hoc test. Percentage
of different cell populations in the thymus was tested by two-
way ANOVA followed by Holm-Sidak multiple comparison tests.
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